Description
Nivolumab is safe and effective in patients with relapsed/refractory lymphoid malignancies and classical Hodgkin lymphoma
€2.42
Nivolumab is safe and effective in patients with relapsed/refractory lymphoid malignancies and classical Hodgkin lymphoma
Reviews
There are no reviews yet.